Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$117.5M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1717.51%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$331.6M
Q3 2024
Cash
Q3 2024
P/E
-4.681
Nov 29, 2024 EST
Free Cash Flow
-$105.5M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $29.97M $33.10M $30.65M $14.20M $7.990M $3.620M $2.620M
YoY Change -9.46% 8.0% 115.82% 77.72% 120.72% 38.17%
% of Gross Profit
Research & Development $113.8M $112.5M $100.1M $49.27M $24.52M $15.53M $17.85M
YoY Change 1.12% 12.43% 103.09% 100.91% 57.91% -13.0%
% of Gross Profit
Depreciation & Amortization $2.148M $2.106M $2.141M $667.0K $493.0K $490.0K $270.0K
YoY Change 1.99% -1.63% 220.99% 35.29% 0.61% 81.48%
% of Gross Profit
Operating Expenses $143.7M $145.6M $130.7M $63.47M $32.52M $19.15M $20.48M
YoY Change -1.29% 11.39% 105.95% 95.18% 69.81% -6.49%
Operating Profit -$143.7M -$145.6M -$130.7M -$63.47M -$32.52M
YoY Change -1.29% 11.39% 105.95% 95.18%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $9.486M $5.000K $10.00K $10.00K $40.00K
YoY Change -50.0% 0.0% -75.0%
% of Operating Profit
Other Income/Expense, Net $9.486M $3.652M $385.0K $57.00K $1.009M $770.0K $1.770M
YoY Change 159.75% 848.57% 575.44% -94.35% 31.04% -56.5%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$134.2M $141.9M -$130.3M -$63.41M -$36.97M -$18.30M -$18.71M
YoY Change -194.57% -208.92% 105.52% 71.51% 102.04% -2.19%
Income Tax $0.00 $0.00 $0.00 $4.000K $0.00 -$5.780M
% Of Pretax Income 0.0%
Net Earnings -$134.2M -$141.9M -$130.3M -$63.41M -$37.18M -$18.30M -$18.71M
YoY Change -5.43% 8.92% 105.52% 70.54% 103.19% -2.19%
Net Earnings / Revenue
Basic Earnings Per Share -$1.77 -$2.60 -$3.40
Diluted Earnings Per Share -$1.77 -$2.60 -$3.401M -$3.739M -$198.5K -$97.71K -$99.90K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $259.7M $242.7M $242.7M $351.2M $43.90M $44.20M $3.000M
YoY Change 7.03% -0.02% -30.89% 700.0% -0.68% 1373.33%
Cash & Equivalents $225.1M $140.0M $74.84M $268.6M $43.90M $44.20M $3.000M
Short-Term Investments $34.61M $102.6M $167.9M $82.60M
Other Short-Term Assets $4.144M $5.441M $4.978M $2.800M $1.400M $1.300M $1.900M
YoY Change -23.84% 9.3% 77.79% 100.0% 7.69% -31.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $263.9M $248.1M $247.7M $354.0M $45.40M $45.70M $4.900M
YoY Change 6.35% 0.16% -30.03% 679.74% -0.66% 832.65%
Property, Plant & Equipment $32.78M $35.97M $38.18M $1.900M $2.100M $2.300M $2.800M
YoY Change -8.85% -5.8% 1909.53% -9.52% -8.7% -17.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.032M $1.032M $1.166M $0.00 $2.400M $100.0K $100.0K
YoY Change 0.0% -11.49% -100.0% 2300.0% 0.0%
Total Long-Term Assets $33.81M $37.00M $39.35M $1.900M $4.500M $2.400M $2.900M
YoY Change -8.61% -5.97% 1970.89% -57.78% 87.5% -17.24%
Total Assets $297.7M $285.1M $287.0M $355.9M $49.90M $48.10M $7.800M
YoY Change
Accounts Payable $5.487M $7.416M $11.15M $3.700M $2.400M $1.300M $1.500M
YoY Change -26.01% -33.51% 201.43% 54.17% 84.62% -13.33%
Accrued Expenses $12.40M $14.76M $10.45M $6.500M $2.200M $1.700M $1.100M
YoY Change -16.01% 41.26% 60.8% 195.45% 29.41% 54.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.93M $22.36M $21.74M $10.60M $4.900M $3.300M $2.900M
YoY Change -19.82% 2.83% 105.13% 116.33% 48.48% 13.79%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $29.19M $31.54M $33.39M $1.000M $1.400M $1.800M $2.100M
YoY Change -7.46% -5.53% 3238.7% -28.57% -22.22% -14.29%
Total Long-Term Liabilities $29.19M $31.54M $33.39M $1.000M $1.400M $1.800M $2.100M
YoY Change -7.46% -5.53% 3238.7% -28.57% -22.22% -14.29%
Total Liabilities $47.12M $53.90M $55.13M $11.70M $6.400M $5.100M $5.100M
YoY Change -12.59% -2.23% 371.21% 82.81% 25.49% 0.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 75.67M 54.67M 38.32M
Diluted Shares Outstanding 75.67M 54.67M 38.32M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $550.02 Million

About Annexon, Inc.

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 84 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). The company is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). The company is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. The company has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.

Industry: Pharmaceutical Preparations Peers: ALPINE IMMUNE SCIENCES, INC. MIMEDX GROUP, INC. Arbutus Biopharma Corp Tango Therapeutics, Inc. Biomea Fusion, Inc. CONCERT PHARMACEUTICALS, INC. GreenLight Biosciences Holdings, PBC Immuneering Corp Omega Therapeutics, Inc.